K-COMPASS: Estimate systemic-therapy free survival following MDT for oligometastatic clear cell RCC
PID: 1178; Version: v1.4.2.0; Last Updated: 04/15/2026
Chad Tang, Alex Sherry, Peng Yang and Pavlos Msaouel
This calculator estimates time off systemic therapy for patients with oligometastatic (≤5 metastases) renal cell carcinoma (RCC) treated with metastasis-directed therapy (MDT) without concurrent systemic therapy.
Patients included had clear cell histology and were off systemic therapy for at least one month before initiating MDT.
No rights can be derived from the information provided.